![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Nivolumab in Patients With Advanced Hepatocellular
Carcinoma: the CheckMate 040 Study
|
|
|
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Bruno Sangro,1Ignacio Melero,1Thomas Yau,2ChiunHsu,3Masatoshi Kudo,4Todd S. Crocenzi,5Tae-You Kim,6Su-Pin Choo,7JorgTrojan,8Tim Meyer,9Theodore H. Welling, III,10Winnie Yeo,11Akhil Chopra,12Jeffrey Anderson,13Christine delaCruz,13LixinLang,13Jaclyn Neely,13HaoTang,13Anthony B. El-Khoueiry141Clinica Universidad de Navarra and CIBERehd, Pamplona, Spain; 2University of Hong Kong, Hong Kong, China; 3National Taiwan University Hospital, Taipei, Taiwan; 4Kindai University Faculty of Medicine, Osaka, Japan; 5Providence Cancer Center, Portland, OR, USA; 6Seoul National University Hospital, Seoul, Korea; 7National Cancer Center, Singapore; 8Goethe University Hospital and Cancer Center, Frankfurt, Germany; 9Royal Free Hospital, London, UK; 10University of Michigan School of Medicine, Ann Arbor, MI, USA; 11Chinese University of Hong Kong, Hong Kong, China; 12Johns Hopkins Singapore International Medical Centre, Singapore; 13Bristol-Myers Squibb, Princeton, NJ, USA;14USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA
![AASLD1](../images/122916/122916-01/AASLD1.gif)
![AASLD2](../images/122916/122916-01/AASLD2.gif)
![AASLD3](../images/122916/122916-01/AASLD3.gif)
![AASLD4](../images/122916/122916-01/AASLD4.gif)
![AASLD5](../images/122916/122916-01/AASLD5.gif)
![AASLD6](../images/122916/122916-01/AASLD6.gif)
![AASLD7](../images/122916/122916-01/AASLD7.gif)
![AASLD8](../images/122916/122916-01/AASLD8.gif)
![AASLD9](../images/122916/122916-01/AASLD9.gif)
![AASLD10](../images/122916/122916-01/AASLD10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|